Dr Lucio D’Anna is a Consultant Neurologist at the Department of Stroke & Neurosciences at Imperial College London NHS Trust. He is also Honorary Senior Lecturer at the Division of Brain Sciences, Imperial College London.
Mild Cognitive Impairment Symptoms
MCI is a condition in which an individual has mild but measurable problems with memory, language, thinking or judgment that are noticeable to the person affected and to family members and that are greater than normal age-related changes. However, cognitive problems are not severe enough to require help with usual activities of daily living. You might be aware that your memory or mental function has “slipped” over the last few months, or your family and close friends may have noticed small changes in your behaviour. These changes usually aren’t severe enough to significantly interfere with your day-to-day life and usual activities.
Mild Cognitive Impairment Diagnosis
We use cutting-edge technology CANTAB, as well neuroimaging such as MRI, amyloid and tau PET to assess the severity of cognitive deficits in people with MCI. This enables us to provide an early diagnosis of cognitive impairment and effectively manage it.
MCI Risk Assessment & Prevention
As with most medical conditions, the sooner you know what is happening, the better. Dementech Neurosciences offers a wide range of cutting-edge services, specifically designed for people with MCI, such as the Dementech Biomarker Tools and genetic counselling appointments. By using the latest advances in imaging and genetics, we are able to answer all your questions regarding the diagnosis, prognosis, monitoring progression and response to treatment.
Mild Cognitive Impairment Treatment
At Dementech Neurosciences, we offer a multidisciplinary approach to treat all the variety of symptoms of MCI. We have in-house speech and language therapist, occupational therapist, dietitian, psychologist and psychiatrist to manage effectively cognitive symptoms. Moreover, we offer the opportunity to participate in clinical trials testing novel pharmacological intervention, before they become available to the public, aiming to delay the progression of the disease. Caregivers may experience significant stresses and have a high level of burden; therefore we also offer caregiver support.